The utility and the limitations of molecular testing for mutations of ATP7B are demonstrated by Butler et al. [1] , who examined the use of single-stranded conformation polymorphism analysis. In six people for whom the diagnosis was uncertain, DNA analyses successfully established their status for Wilson disease. This analysis was also used to identify presymptomatic people in families affected by Wilson disease. People previously diagnosed as having Wilson disease were instead established as heterozygote carriers or given wild-type status. In 26 patients with Wilson disease, 92% of disease alleles were identified by their studies. That 100% of disease alleles were not identified suggests limitations to current techniques or the possibility of other, unidentified genetic aberrations that contribute to a phenotype of Wilson disease. Advances in technology for DNA sequencing and mutation analysis should aid future molecular diagnosis of this disorder.
In an unusual use of molecular diagnosis, the diagnosis of Wilson disease was suspected posthumously in a patient originally suspected of having alcoholic cirrhosis and Parkinsonism [2] . Because the body of the person was cremated, the DNA for the analysis was obtained from an electric shaver that had been saved and unused for 5 years after the patient's death. In the deceased, two of Biochemical and clinical evaluations confirmed heterozygosity and absence of disease in these other family members.
Iron accumulation in the livers of four male patients in Japan was an interesting consequence of chelation treatment for Wilson disease with D-penicillamine [3•]. Over time, these people developed continued elevations in transaminase levels, and some developed elevations in serum ferritin. The ceruloplasmin oxidase levels decreased in these patients, and the nonceruloplasmin copper levels were calculated to be very low [3•] . Repeat liver biopsy showed elevated liver iron detectable histochemically and on quantitative analysis, and phlebotomy therapy was used to treat these people. This report and the accompanying editorial [4•] highlight the interesting interaction between copper and iron metabolism: copper chelation treatment likely reduced the function of proteins with ferroxidase activity such as ceruloplasmin and possibly hephaestin. Levels of circulating nonceruloplasmin bound copper should be monitored as a parameter for adjusting dosages of chelating agents when treating patients with Wilson disease; the value is best estimated by subtracting the amount of copper in ceruloplasmin from the total serum copper. Most of the past focus has been on lowering the value of nonceruloplasmin copper in newly treated patients, but this report highlights that this value can be too low, with resultant hemosiderosis. Ideally, future work will define the acceptable lower limits of nonceruloplasmin copper for patients treated for Wilson disease.
Zinc is an effective maintenance therapy for Wilson disease that acts mainly by preventing copper absorption at the level of the enterocyte. Only scattered case reports have documented its use in pediatric patients. Brewer et al. [5••] describe their clinical experience in 34 patients treated with zinc, age 3 to 17 years, followed until age 19 years. Safety and efficacy of the treatment was shown for zinc 25 mg twice daily for those age 1 to 5 years, 25 mg thrice daily for age 6 to 15 years, and 50 mg three times daily for those greater than 125 lb or older than 16 years. The only side effects were transient gastric intolerance in four patients and reduction of the high-density cholesterol to total cholesterol ratio. The importance of the latter finding in this population is uncertain; of interest, the finding was contrary to results in adults, in whom lipoprotein profiles did not seem adversely affected by zinc treatment. Overall, this report represents an important contribution to the reported experience of treating pediatric patients with Wilson disease.
The natural history of untreated severe hepatic insufficiency caused by Wilson disease is progression to liver failure and death. Durand et al. [6•] reiterate this natural history of the disease in four of their patients observed before 1979. After that time, those patients with Wilson disease with hepatic insufficiency but without encephalopathy were treated with D-penicillamine. Of the 11 in this group, 10 were successfully treated with this drug and stabilized, and one progressed and required orthotopic liver transplantation (OLT). Similar results were noted in a preliminary report by Schilsky and Shneider [7] in which four patients with severe hepatic insufficiency were treated with a combination of zinc and trientine with good results, although two later suffered complications of bleeding from portal hypertension, requiring a splenorenal shunt in one and transplantation in the other. Together, these reports highlight the need for early diagnosis of Wilson disease but also the ability to treat some patients with severe disease medically. The decision to treat these patients medically requires a commitment to close follow-up, which may include evaluation by a liver transplant center in case the patient's status deteriorates.
Orthotopic liver transplantation corrects the Wilson disease phenotype and provides excellent long-term survival. Results of a series of 21 patients transplanted for Wilson disease were reviewed [8•]. Eleven were transplanted for fulminant hepatitis and six for severe hepatic insufficiency despite therapy. One-year survival was 87.5%, and those who survived had excellent long-term survival. Renal insufficiency was found in many of these patients and was likely exacerbated by tubular injury from copper and the renal insufficiency that can develop as part of the multiorgan failure associated with acute liver failure. Although some of these people required transient support with dialysis, renal function uniformly recovered with time. This study reconfirmed that indications for transplant for Wilson disease include acute fulminant hepatic failure, progressive hepatic insufficiency despite therapy, and complications of portal hypertension caused by cirrhosis, such as recurrent bleeding. As seen in some earlier studies, neurologic symptoms present before OLT may improve after transplant. However, it is my recommendation that OLT not be recommended for those with neurologic symptoms alone, because some improvement is possible with medical treatment, and progression of liver disease is prevented as well. Although there are some reports of transplantation being performed for neurologic Wilson disease [9], given the current scarcity of donor organs, these organs are best used for those in whom stabilization of liver disease is not possible.
Although OLT remains an effective therapy for Wilson disease, it was uncertain whether the replacement of only part of the mass of normal hepatocytes was capable of correcting the metabolic defect and yielding a normal phenotype. Using an animal model of Wilson disease, the Long-Evans Cinnamon rat, Irani et al. [10•] demonstrated that repopulation of the liver with approximately 40% or greater mass of normal hepatocytes obtained from the congeneic parental strain of Long-Evans Agouti rat could restore adequate biliary copper excretion, lower hepatic copper content, and prevent further liver damage that would have occurred spontaneously otherwise. However, to obtain substantial repopulation, treatment with retrorsine and partial hepatectomy was used. This work represents the first demonstration of complete restoration of normal phenotype by liver cell transplant and should pave the way for future studies to find alternatives for obtaining repopulation that could be used in human trials.
Dystonia, a common problem for patients with neurologic manifestations of Wilson disease, was present in more than one third of 27 Yugoslavian patients with neurologic presentations of Wilson disease [11] . In these people, MRI of the brain detected involvement of the putamen in 80%, compared with only 24% in those without dystonia. These data suggest a relation between dystonic movements and this structural region of the brain in Wilson disease.
Svetel et al.
[12] described a patient with neurologic Wilson disease who developed a lethal status dystonicus with generalized dystonia and rigidity. This patient was treated with D-penicillamine with a gradual increase in the daily dosage to 1250 mg after 4 weeks, when dramatic neurologic worsening occurred with generalization of the dystonia that led to rhabdomyolysis, renal failure, and eventual death. Although an uncommon occurrence, this report highlights the potential problem of worsening neurologic disease associated with initial D-penicillamine use for the treatment of Wilson disease and the need to consider alternative therapies for these patients.
The presence of visual disturbances has been only rarely reported in patients with Wilson disease. One such case occurred in a 46-year-old man who sought treatment for end-stage liver disease caused by Wilson disease, diagnosed by Kayser-Fleischer rings, a slightly low ceruloplasmin, elevated urinary copper, and cirrhosis [13] . In addition, this patient had rapidly progressive optic neuropathy that began during the investigation of the cause of his illness. Other known causes of retinal disease and optic neuropathy were excluded, and the patient failed to respond to a trial of steroids, with continued rapid visual loss and eventual blindness. Unfortunately, longer follow-up was unavailable. The patient required OLT for progressive disease despite D-penicillamine treatment, and died soon after because of primary nonfunction of the new graft.
Cell biology of ATP7B protein and other proteins involved in copper metabolism
The protein encoded by the Wilson disease gene, ATP7B, is a P-type ATPase that transports copper across membranes. The cysteine rich N-terminus is capable of copper binding postulated to be important for copper transport by signaling posttranslational changes in the ATP7B protein at distal sites. Evidence for such a role for ATP7B protein was provided by Vanderwerf et al. [14•] , who demonstrated that a basal phosphorylation site exists on the C-terminus of the protein, and that phosphorylation is copper-dependent at a second site. These data provide further insight into the structure and function of this interesting protein.
The relocation of ATP7B protein from the trans-Golgi in the basal state to an endosomal compartment in the presence of elevated copper concentrations is postulated to allow increased transport of copper into the pathway for biliary export in times of copper abundance. The toxic milk mutation (tx) in mice in the ATP7B homologue WND results in a phenotype similar to that of Wilson disease. La Fontaine et al.
[15•] expressed the WND protein in Chinese hamster ovary cells and demonstrated an increased resistance to copper. In response to increased copper exposure, the WND protein was sorted to subcellular structures resembling late endosomes. When the WND protein with the tx mutation was introduced into the same cell line, these cells failed to develop copper resistance and failed to relocate the WND tx protein to the late endosomes from the trans-Golgi. These data provide evidence for the copper-induced change in subcellular location of WND protein in response to copper, and suggest that the change in responsiveness to copper may be responsible, in part, for the tx mouse phenotype (Fig. 1) .
The importance of transport proteins for copper is highlighted by the studies of the proposed cell surface transporter Ctr1 by Lee et al. [16•] . In initial studies of the in vitro overexpression of the Ctr1 protein in human kidney cells, copper uptake was stimulated 30-fold. This finding prompted studies in mice in which deletion of one copy of the Ctr1 gene led to alterations in the copper content of organs, with half the normal amount of copper in brains and spleens of these animals. The researchers next found that the lack of Ctr1 in mice resulted in embryonic lethality, demonstrating the critical need for copper during development. Based on these data, it is likely that homozygous Ctr1 mutations in humans would be lethal, but that heterozygosity is possible. Whether heterozygosity exists for mutations of this gene in humans and whether these mutations have clinical consequence remains to be determined.
Determining the pathways by which copper traffics within cells has attracted attention. Specifically, proteins that function as chaperones for shuttling copper to specific sites within cells have been the subject of great interest. Hazma et al. [17•] examined the role of the metallochaperone Atox1 in knockout mice lacking expression of this gene. Forty-five percent of the pups who were Atox1 -/died before weaning, and the survivors demonstrated considerable growth retardation and congenital malformations, phenotypes consistent with copper-deprived animals. Interesting differences were also observed in expression of the phenotype of the offspring, depending upon the maternal genotype. Other biochemical studies of mouse embryonic fibroblasts from these Atox1 knockout mice recorded a phenotype showing copper retention similar to that of Menkes disease fibroblasts. Together, these studies point to an important role for the metallochaperone Atox1 in copper transfer, the essential role of copper in development, and the complex interaction of genetic influences on maternal nutrient delivery to the developing fetus.
Genetic hemochromatosis and iron overload disorders
There are numerous recent reports on genetic hemochromatosis, including an excellent overall review on the chemistry and biology of iron metabolism by Aisen et al.
[18] and important reviews on genetic hemochromatosis that focused on the diagnosis and management of this disorder [19•,20•] . A practice guideline by the American Association of the Study of Liver Disease [19•] sets forth a diagnostic algorithm. Initial screening of patients includes measurement of serum transferrin saturation and ferritin. HFE genotype analysis was recommended for those with elevated values of these tests and for firstdegree relatives of patients with a known genotype con-sistent with genetic hemochromatosis. Liver biopsy was used for heterozygous patients older than 40 years, those with elevated ferritin greater than 1000 ng/mL, and those with nondefinitive HFE genotype studies. Phlebotomy continues to be the mainstay of treatment, with a target ferritin of 25 to 50 ng/mL. Another review [20•] includes similar recommendations and a discussion of determining iron status and HFE genotype in patients with other liver diseases such as porphyria cutanea tarda, nonalcoholic steatohepatitis, and chronic hepatitis C virus.
The presence of oxidative stress and chronic inflammation in metal overload disorders is associated with oxidative damage to DNA. Because approximately 30 to 40% of all hepatocellular carcinomas develop p53 mutations, Hussain et al. [21] explored whether there was an increase in the numbers of p53 gene mutations in noncancerous liver tissue from patients with genetic hemochromatosis or Wilson disease. Using a sensitive genotypic mutation analysis, they examined specific codons from p53 for base pair transversions, and found increased numbers of mutations in liver samples from both genetic hemochromatosis and Wilson disease patients compared with controls. Immunohistochemically, they demonstrated increased levels of inducible nitric oxide synthase in 28% of genetic hemochromatosis samples and 60% of the Wilson disease samples, suggesting that this induction could lead to increased nitric oxide production resulting in oxidative DNA damage. These data provide a link between excess metals and oxidative DNA damage and the increased incidence of liver tumors in genetic hemochromatosis. The absence of a similar increased incidence of tumors in Wilson disease could be the result of treatment for Wilson disease, without which patients with Wilson disease and liver disease rarely live beyond their fourth decade.
The possibility of a gut-liver link in the regulation of iron absorption has been considered for many years, but the link has never been discovered. With the discovery of a new peptide called hepcidin, understanding of the possible link to hemochromatosis and anemia of chronic disease may be one step closer. Three separate studies performed for very different reasons all led to the discovery of hepcidin and have helped formulate its role in iron homeostasis. Park et al. [22•] searched for an antimicrobial peptide that they isolated from the urine, and traced the synthesis of an 84-amino acid peptide that they called hepcidin to the liver. In a study by Nicolas et al.
[23•] that examined the phenotype of the upstream stimulatory factor 2 knockout mouse model, it was noted that these animals had severe tissue iron overload. By molecular techniques of suppressive subtractive hybridization, the cDNA encoding hepcidin was found to be missing in these mice. In a third study by Pigeon et al.
[24•], hepcidin was identified as a protein that was over- 
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Shown on the left is the production and trafficking of the mouse homologue of the ATP7B protein in normal mouse hepatocytes. In response to copper, the protein that localizes mainly in the trans-Golgi in the basal state moves to an endosomal compartment, and then transfers its contents to lysosomes and to bile. As an alternative pathway, the protein itself moves to the canaliculus, where it may act as a copper transporter directly. In the toxic milk mouse, the WNDtx gene gives rise to a mutant protein that does localize to the trans-Golgi in the basal state but that does not migrate out in response to copper. This defect in the trafficking is thought to contribute to the phenotype of copper accumulation and injury in the liver of these mutant mice. ER, endoplasmic reticulum. Adapted with permission [15•]. expressed in the liver during iron overload. This identification was accomplished using suppressive subtractive hybridization between control and iron-loaded mice by experimental iron overloading, or spontaneously because of absence of ␤ 2 -microglobulin. The identification of iron loading in the absence of hepcidin expression and the overexpression of the protein in the liver after iron overload suggest that this protein plays an important role in iron homeostasis. How it functions in this capacity remains to be determined, but it is an attractive candidate for the gut-liver link.
There is increasing recognition that some people homozygous for HFE C282Y do not express substantial iron overload, suggesting a role for other genetic and environmental modifiers in susceptibility to iron loading. To investigate this idea, Hfe knockouts were created using three different mouse strains [25] . These studies demonstrate clear differences in phenotypic expression, with differing levels of iron accumulation identified when animals were fed basal diets. These results suggest that molecular genetic techniques can be used to help tease out the genes responsible for susceptibility to iron loading, and that in the future, the potential iron overload in susceptible people might be predicted better.
Since the discovery of the HFE gene, familial iron overload has been recognized to occur in patients lacking HFE mutations, such as those with mutations of transferrin receptor 2. Mutations in other genes involved in iron metabolism were identified as responsible for the hemochromatosis phenotype in recent reports. Table 1 lists some of the genes responsible for iron overload disorders, including the new descriptions that follow.
The mutation in the iron-responsive element of the mRNA for the H subunit of ferritin identified by Kato et al. [26••] was associated with iron overload in a 56-yearold woman and two of her siblings but not her 26-yearold daughter with the same mutation. The mutation in the iron-responsive element causes it to bind the ironresponsive protein with greater affinity, suppressing translation of the H subunit mRNA. The lack of H subunit, the site of ferroxidase activity for the ferritin protein, results in decreased iron uptake into the ferritin molecule and cytosolic iron accumulation, as demonstrated by in vitro iron incorporation studies in COS-1 cells, in which the mutant subunit was expressed. It is interesting that the knockout of the H-ferritin gene in mice leads to early embryonic lethality caused by massive iron deposition [27] , whereas in this study, a lack of iron loading was observed in the daughter. Further study is needed to elucidate the factors that modify expression of the genotype.
Two separate reports demonstrated mutations in another protein involved in iron metabolism, ferroportin, which that serves as the portal for iron efflux from cells These mutations are proposed to impair its activity for iron export, leading to cellular iron accumulation. In both studies, there were younger patients who had not yet developed evidence of iron loading, not dissimilar to the phenotypic expression of HFE-dependent genetic hemochromatosis. Because anemia was not prominent in the people observed in one of the studies, tissue iron accumulation may compensate for the decreased efficiency of iron recycling.
The regulation of the proteins involved in iron absorption into enterocytes, DMT1, and efflux from these cells, ferroportin 1, in states of iron deficiency and iron overload were determined by Zoller et al. [30•] in human duodenal specimens. The study group included healthy people, patients with iron deficiency, and others with chronic liver disease. DMT1 and ferroportin 1 mRNA expression estimated by quantitative polymerase chain reaction and DMT1 protein expression estimated by Western blot showed a positive correlation between the expressions, with the highest levels of both found in patients with iron deficiency. Patients with HFEassociated and non-HFE-associated iron overload and those with iron deficiency had elevated DMT1 and ferroportin 1 mRNA and DMT1 protein, whereas patients with secondary iron overload and chronic liver disease had lower levels of DMT1 mRNA and protein. These data show that the regulatory pathways for iron are functional in secondary iron overload but are uncoupled in genetic disorders of iron overload.
␣ 1 -Antitrypsin
Several interesting studies researched ␣ 1 -antitrypsin deficiency and liver disease. Liver transplant remains the only effective treatment for advanced liver disease caused by ␣ 1 -antitrypsin deficiency, although knowledge of the natural history indicates that many patients do not develop progressive liver disease unless they suffer a second insult. New data on the clearance system for ␣ 1antitrypsin add to understanding of the pathophysiology of this disorder and ideally will help in the development and assessment of new therapeutics.
Liver disease caused by ␣ 1 -antitrypsin deficiency is typically associated with very low levels of circulating ␣ 1antitrypsin and PiZ phenotype. Canva et al.
[31] report on a patient without history of childhood liver disease who sought treatment for jaundice and progressive liver failure. The patient ultimately required liver transplantation at age 59 years. Although circulating levels of ␣ 1antitrypsin were lowered by approximately 50% in this patient, the presence of heterozygosity for the MMalton phenotype led to demonstrable hepatocellular retention of ␣ 1 -antitrypsin. Interestingly, two siblings of the patient had cryptogenic cirrhosis, one with decompensated disease. The MMalton mutation caused hepatocellular retention of ␣ 1 -antitrypsin and its reduction in the circulation.
There are more than 75 variants of ␣ 1 -antitrypsin separable by their isoelectric point; however, the differences are often very subtle, and the diagnosis of specific subtypes is difficult. Lima et al.
[32] report on the use of molecular analysis for ␣ 1 -antitrypsin on a cohort of 29 Brazilian patients with liver disease seeking treatment at age 2 months to 18 years with cirrhosis or cholestatic jaundice, and 100 controls (93 white, 5 Asian, 2 black). Of the 58 alleles analyzed from the patients with liver disease, seven had the Glu 342 to Lys mutation, a frequency of 12.06% for the PiZ allele, with one homozygous for PiZ. In the controls, one patient was heterozygous, yielding an allele frequency of 0.5% (1/200), slightly higher than that of another Brazilian study with a white population, but lower than any of the reported frequencies in some European populations. The relatively high frequency of detection of ␣ 1 -antitrypsin mutations in the population with liver disease, especially in the neonatal period, shows the utility of molecular analysis for mutations and the histologic demonstration of ␣ 1 -antitrypsin globules on liver biopsy.
The degradation of the PiZ ␣ 1 -antitrypsin protein in the liver is thought defective in those who develop progressive liver disease caused by ␣ 1 -antitrypsin deficiency. The normal clearance is thought to involve the ubiquitin-proteosomal degradation system. To study the role of this system in ␣ 1 -antitrypsin liver disease, Wu et al. [33] examined the distribution of ubiquitin in livers from 14 people with ␣ 1 -antitrypsin deficiency (12 cirrhotic explant livers) and 10 controls from autopsy specimens. In seven of the cirrhotic livers, ubiquitin was strongly immunoreactive and detectable in the cytoplasm, but in five, there was only focal positivity in less than 5% of hepatocytes. By contrast, in controls the ubiquitin was diffuse, weak, and evenly distributed within hepatocytes. These data show that ubiquitin is increased in PiZZ livers, consistent with the lack of degradation in the endoplasmic reticulum, where the protein is retained. Interpretation of the data is limited because the explant livers represent end-stage disease and data from earlier time points were not available; however, future prospective analysis may elucidate the natural history of these changes.
Conclusions
Important recent contributions include reports on zinc treatment of pediatric patients with Wilson disease, an update on liver transplantation, and new information on the function of a gene product responsible for Wilson disease, the ATP7B protein. For disorders of iron metabolism, the exciting discoveries were the molecular basis for non-HFE autosomal dominant iron overload disorders and a novel protein that could be the gut-liver link in iron homeostasis, hepcidin. Liver transplant remains an effective cure for ␣ 1 -antitrypsin deficiency and prevents the development or progression of pulmonary disease. New information about the cellular pathway for the metabolism of mutant ␣ 1 -antitrypsin increases our knowledge of the pathophysiology of this disorder. The recognition that certain mutations in the heterozygous state can lead to liver disease suggests that clinicians should continue to screen with levels of the protein and for Pi typing, and perhaps use molecular analysis in the future. A report on the occurrence of hepatic iron accumulation in four male patients treated with penicillamine that highlights the interesting interaction of copper and iron metabolism. The chelation treatment caused ceruloplasmin oxidase levels to decrease. Repeat liver biopsy showed elevated liver iron detectable histochemically and on quantitative analysis. Phlebotomy therapy was used for treatment. 137:191-198 . This report describes the clinical experience for 34 pediatric patients aged 3 to 17 years treated with zinc and their follow-up until age 19 years. Safety and efficacy of the treatment was shown for zinc 25 mg twice daily for those aged 1 to 5 years, 25 mg three times daily for ages 6 to 15 years, and 50 mg three times daily for those more than 125 lb or older than 16 years. The only notable side effect was transient gastric intolerance in four patients.
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